Rheumatoid arthritis
Conditions
Interventions
TNF-inhibitors plus MTX TNF-inhibitors are used for 54 weeks and exchange among them is approved
MTX MTX is used for 54 weeks and addition of the other DMARD is approved
Sponsors
School of Medicine, University of Occupational and Environmental Health, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be enrolled in this study: 1) Patients with RA diagnosed according to the criteria of the American College of Rheumatology (ACR) (1987) 2) Patients who develop develop moderate or high activity, despite NSAID and/or DMARD therapy 3) Patients who agreed to practice an appropriate contraception during the study period
Exclusion criteria
Exclusion criteria: Patients who met the following criteria are excluded. 1. patients with contra-indication to MTX 2. patients with contra-indication to TNF-inhibitors 3. patients who are not appropriate to the study by a doctor's judgement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of reduction of joint destruction between TNF-inhibitors and MTX alone. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) new bone erosion (2) DAS28 (3) EULAR-improvement criteria (4) HAQ | — |
Countries
Japan
Contacts
Public ContactKazuyoshi Saito
School of Medicine, University of Occupational and Environmental Health, Japan First Department of Internal Medicine
Outcome results
None listed